ICON Plc Stock News

DUBLIN--(BUSINESS WIRE)--ICON Announces CEO Transition.

DUBLIN--(BUSINESS WIRE)--ICON plc to Participate at Upcoming Investor Conferences.

In the world of healthcare stocks, a major innovation, new medical device, or successful drug treatment can cement a firm's position as a leader. Unfortunately, many firms chase after these goals and never achieve them.

ICON Public Limited Company (NASDAQ:ICLR ) Q2 2025 Earnings Conference Call July 24, 2025 8:00 AM ET Company Participants Barry Balfe - Chief Operating Officer Kate Haven - Vice President of Investor Relations Nigel Clerkin - Chief Financial Officer Steven A. Cutler - CEO & Director Conference Call Participants Charles Rhyee - TD Cowen, Research Division David Howard Windley - Jefferies LLC, Re...

ICON may be relatively undervalued, trading at a ~10% discount to IQVIA and offering an attractive ~7% free cash flow yield that markets seem to be responding to now. The CRO sector faces near-term headwinds from a weak biotech funding environment related to high interest rates and associated increased clinical trial cancellations and delays. Q2 is indicating to markets that there will eventual...

DUBLIN--(BUSINESS WIRE)--ICON Announces Results of Annual General Meeting.

DUBLIN--(BUSINESS WIRE)--ICON Reports Second Quarter 2025 Results.

DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been rated as one of the top-performing contract research organisations (CRO) for phase 1 clinical trials in a benchmarking report from the independent pharmaceutical market research company Industry Standard Research (ISR). ICON outpaced the average phase 1 performa...